Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

apies, Inc. ("Shire"), is engaged in ongoing discussions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) and will provide an update by the end of the year. A final decision on the global development strategy will follow the conclusion of the discussions with both agencies. Subject to the outcome of the discussions, the Company expects to initiate Phase 3 development of Amigal in the first half of 2009.

In addition, 23 of the original 26 patients continue to be treated in a voluntary Phase 2 extension study designed to monitor long-term safety and efficacy and to evaluate additional doses and dose regimens. Data from this extension study are expected in Q1 2009 prior to the start of the Phase 3 study.

Gaucher Disease:

Plicera(TM) (isofagomine tartrate) is an investigational, oral therapeutic in Phase 2 development for the treatment of Gaucher disease. As previously disclosed, a 6-month Phase 2 clinical trial of Plicera in patients naive to ERT is ongoing and Amicus expects the results of this study to be available in 2009.

Pompe Disease:

AT2220 (1-deoxynojirimycin HCl) is an investigational, oral therapeutic being developed for the treatment of Pompe disease. As previously disclosed, a Phase 2 clinical trial of AT2220 in adult Pompe patients is ongoing and includes an 11 week treatment period with an optional extension study.

In addition, Amicus is conducting preclinical animal studies to evaluate the effects of administering AT2220 in combination with enzyme replacement therapy. Based on the results of the preclinical work, Amicus will consider initiating a clinical trial of the AT2220-ERT combination treatment in Pompe patients.

Other Chaperone Programs:

Amicus continues to invest in research and development to assess the potential for using pharmacological chaperones to treat a broader range of human genetic diseases beyond lysosomal storage diseases. As part of this
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Calif. , March 2, 2015 ... company developing therapies for autoimmune and infectious diseases, ... (USPTO) has issued an important new composition of ... function through the targeting of CLIP. ... peptide technology underlying VG Life Sciences, VG1177, a ...
(Date:3/2/2015)... 02, 2015 Outside GC, the leading ... the addition of Debbie Casey as a member of ... healthcare space. , Debbie has spent over ... with Fresenius Medical Care North America in both legal ... experience to work with Outside GC’s growing list of ...
(Date:2/27/2015)... 27, 2015 Immunovaccine Inc. (“Immunovaccine” or ... a fraudulent press release disseminated this morning by PR ... Immunovaccine. This press release states that Immunovaccine has entered ... The press release did not originate from Immunovaccine and ... the press release. Please note that all official ...
(Date:2/27/2015)... CAMBRIDGE, Mass. , Feb. 27, 2015 /PRNewswire-USNewswire/ ... Analysis of the NCATS rare-diseases portfolio " in ... of a new financing technique to reduce the ... new diseases and potentially unlock new levels of ... The product of a unique collaboration between ...
Breaking Biology Technology:VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3Outside GC Expands Healthcare Team 2Immunovaccine Disclaims Hoax Press Release 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4
... businesses seek to protect and enhance the value of ... of the business' products and services. Each year, several ... of them for federal trademark registration. Indeed, applications for ... leading indicator of economic conditions (a steep drop in ...
... Search engine experts have been hounding Google to accept XML ... When Google recently introduced the beta version of Google ... - at least in part. , ,Google Sitemaps is a ... with frequently updated or changing content. It ensures that the ...
... for the first time, China has 100 million people on ... a few years, a billion people in Asia will be ... replicating at a phenomenal rate will create global shockwaves both ... including India and several other highly populated countries, is not ...
Cached Biology Technology:Why file for trademark protection? 2Why file for trademark protection? 3Why file for trademark protection? 4Givin' it to Google: Using an XML Sitemap to Boost Your Site 2Givin' it to Google: Using an XML Sitemap to Boost Your Site 3Huge cyber-tsunami developing in Asia 2Huge cyber-tsunami developing in Asia 3
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America recently ... for carbon nanotube (CNT) macrostructures, including sheets, yarns and ... (UTD). Leveraging the vast industrial resources of ... Japan , Lintec of America is forming the ... TX , focusing on scaling up the manufacturing ...
(Date:2/5/2015)... 2015  Marken is starting its 35 th ... a new marketing campaign to solidify its place as ... campaign focuses on First as a primary ... The first headline in the series, ... its client,s priorities. Marken recognizes the need to protect ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2
... Khalid Iqbal Lifetime Achievement Award" for its role as ... disease. The award ceremony was held yesterday (10:45 am ... International Conference (AAIC 2013)" in Boston (USA). Eva-Maria ... progress in Alzheimer,s research in the course of their ...
... avian H7N9 influenza that emerged in China this year have ... the infection, but testing for antiviral resistance can give misleading ... The authors of a study published in mBio , ... characterized viruses taken from the first person known to be ...
... -- United Medical Education, a leading online certifying institution ... Pediatric Advanced Life Support (PALS), and Basic Life Support ... course materials for its ACLS online renewal ... online courses. (Photo: http://photos.prnewswire.com/prnh/20130715/MN47087 ) ...
Cached Biology News:Pioneers in Alzheimer's research: Research couple honored for its lifetime achievement 2Pioneers in Alzheimer's research: Research couple honored for its lifetime achievement 3H7N9 influenza strain resistant to antivirals, but tests fail to identify resistance 2H7N9 influenza strain resistant to antivirals, but tests fail to identify resistance 3ACLS Online Renewal Course from United Medical Education Now Features Newly-Updated Course Materials 2
alpha-N-Catenin Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Bovine Endometrium Epithelial Cells (BEnEpC) (>500,000 cells)...
... Darkroom is designed for imaging of chemiluminescent, ... systems offer direct control for users who ... by hand , A range of high ... for all fluorescent and chemiluminescent applications ...
... smooth muscle cell specific protein, is reported to ... such as intestine, lung and uterus. It shares ... alpha expression has been reported in most tissues ... visceral forms. It is also reported to be ...
Biology Products: